Skip to content
Patient Portal
Abington Neurological Associates
  • Home
  • About
  • News
  • Providers
    • Lee J. Harris, MD
    • James H. Cook, MD
    • David C. Weisman, MD
    • Brad C. Klein, MD
    • Dan J. Gzesh, MD
    • John S. Khoury, MD
    • Kandan Kulandaivel, MD
    • Kartik Sivaraaman, MD
    • Steven D. Factor, MD
    • Diana Li, MD
    • Minsoo Kim, MD
    • Sarah S. Smith, CRNP
    • Karen Chen, PA-C
    • Rinsu Varghese, CRNP
  • Services
    • EMG
    • EEG
    • Botox
    • Sleep Disorders
    • Infusions
      • Infusion Medications
    • Medical Marijuana
  • Conditions
    • Alzheimer’s Disease
    • Carpal Tunnel Syndrome
    • CIDP
    • Dementia
    • Epilepsy and Seizures
    • Guillain-Barré Syndrome
    • Headache
    • Insomnia
    • Multiple Sclerosis
    • Myasthenia Gravis
    • Myopathy
    • Narcolepsy
    • Parkinson’s Disease
    • Peripheral Neuropathy
    • Restless Legs Syndrome
    • Sleep Apnea
    • Stroke
    • TIA
    • Tremor
  • Forms
  • Resources
  • Telemedicine
  • Contact
  • Research
    • About ANA Clinical Research
    • Alzheimer’s Trials
    • In the News
    • Research Newsletter
    • COVID19
  • Webinars

Alzheimer’s Disease: Mystery No More

May 18, 2021

It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.

Alzheimer’s Disease: Mystery No More Read More »

Trailblazer clinical trial featured in New York Times

April 28, 2021

In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.

Trailblazer clinical trial featured in New York Times Read More »

Trailblazer clinical trial featured in New England Journal of Medicine

March 14, 2021

In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.

Trailblazer clinical trial featured in New England Journal of Medicine Read More »

Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease

January 11, 2021

Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.

Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease Read More »

Missing bill payments could be an early sign of dementia

December 8, 2020

Alzheimer’s disease and related dementias were associated with adverse financial events starting years prior to clinical diagnosis.

Missing bill payments could be an early sign of dementia Read More »

ANA Presentation at CTAD 2020

November 12, 2020

The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.

ANA Presentation at CTAD 2020 Read More »

Dr. Weisman interviewed on Senior Advocates, Who’s Who

October 30, 2020

Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.

Dr. Weisman interviewed on Senior Advocates, Who’s Who Read More »

A New Treatment for Migraine

July 27, 2020

Thanks to the latest research, we can now target specific migraine pathways.

A New Treatment for Migraine Read More »

Infusions Explained

June 1, 2020

Infusion therapy may seem modern, but its origins trace as far back as 1492.

Infusions Explained Read More »

Dr. Weisman interviewed in Neurology Insights

May 20, 2020

Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.

Dr. Weisman interviewed in Neurology Insights Read More »

← Previous 1 2 3 4 … 6 Next →
© 2025 Abington Neurological Associates
Phone: 215-957-9250
Fax: 215-957-9254
1151 Old York Road, Suite 200, Abington, PA 19001